Centauri Therapeutics: Venture Capital Funding History
Centauri Therapeutics
To add a bio or update company history, please click update information.
News from Centauri Therapeutics
Centauri Therapeutics
24 Feb 2026
Centauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapy
Centauri Therapeutics is a biotechnology startup developing immunotherapies using its Alphamer platform. Its treatments are designed to harness the body’s immune response to target infectious diseases, including multidrug-resistant bacteria.
Centauri Therapeutics
29 Jul 2025
Centauri Therapeutics secures a further £3.8m from CARB-X to advance antimicrobial candidate into clinical trials
Centauri Therapeutics develops antimicrobial therapies based on a proprietary immunotherapy platform, with its lead candidate designed to treat serious drug resistant bacterial infections of the lung.
Centauri Therapeutics
- Life Sciences
- Cheshire, United Kingdom
- £9.8m
- centauritherapeutics.com
- Update Information
More venture news
- 10 Nov 2026
Neobe TherapeuticsNeobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
SeedLife Sciences - 9 Nov 2026
PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences - 5 Nov 2026
Alethio TherapeuticsAlethio Therapeutics secures a £67m Series A round led by Sofinnova Partners and RA Capital to develop targeted blood cancer therapies
Series ALife Sciences
